French biotechnology firm TxCell has appointed Prof Zelig Eshar, Prof Chiara Bonini and Dr Bernard Malissen to its newly-formed scientific advisory board.
As members of the board, they will be responsible for monitoring and guiding the research and development of TxCell’s ASTrIA and ENTrIA platforms as well as advising on the development of the company’s existing and pipeline drug candidates.
Prof Zelig Eshar (pictured above) has been appointed as chairman of the scientific advisory board and brings over 40 years of immunology expertise to the role.
He is currently professor emeritus at The Wiezmann Institute of Science and chairman of immunology research at the Tel Aviv Sourasky Medical Center.
Prof Chiara Bonini (pictured left) is currently head of the experimental hematology unit at the San Raffaele Scientific Institute, a position she has held since 2008.
She also serves as associate editor of the Journal of Gene Medicine, and is a member of the board of the European Society of Gene and Cell Therapy.
Dr Bernard Malissen (pictured below) brings over twenty years of molecular immunology experience to the board, most recently from the Marseille-Luminy Immunology Center, which he helped to develop.
Dr Malissen is a member of the French Academy of Sciences, the European Molecular Biology Organisation and is an honorary member of the American Association of Immunologists.
Arnaud Foussat, chief scientific officer of TxCell, said: “TxCell has managed to build a SAB that is unparalleled in the cell immunotherapy sector and this matches and adds to its global leadership in the promising field of Treg Cells.
“TxCell now has access to a knowledge and experience resource that will provide guidance to the development of our existing product pipeline … [and] will also play a key role in helping TxCell to create novel and innovative cellular immunotherapy products.”